Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
J Thromb Haemost. 2015 Jun;13(6):989-97. doi: 10.1111/jth.12908. Epub 2015 Apr 18.
Coagulopathy has a high prevalence in critically ill patients. An increased International Normalized Ratio (INR) is a common trigger to transfuse fresh frozen plasma (FFP), even in the absence of bleeding. Therefore, FFP is frequently administered to these patients. However, the efficacy of FFP in correcting hemostatic disorders in non-bleeding recipients has been questioned.
To assess whether INR prolongation parallels changes in the results of other tests investigating hemostasis, and to evaluate the coagulant effects of a fixed dose of FFP in non-bleeding critically ill patients with a coagulopathy.
Markers of coagulation, individual factor levels and levels of natural anticoagulants were measured. Also, thrombin generation and thromboelastometry (ROTEM) assays were performed before and after FFP transfusion (12 mL kg(-1) ) to 38 non-bleeding critically ill patients with an increased INR (1.5-3.0).
At baseline, levels of factor II, FV, FVII, protein C, protein S and antithrombin were reduced, and thrombin generation was impaired. ROTEM variables were within reference ranges, except for a prolonged INTEM clot formation time. FFP transfusion increased the levels of coagulation factors (FII, 34% [interquartile range (IQR) 26-46] before vs. 44% [IQR 38-52] after; FV, 48% [IQR 28-76] before vs. 58% [IQR 44-90] after; and FVII, 25% [IQR 16-38] before vs. 37% [IQR 28-55] after), and the levels of anticoagulant proteins. Thrombin generation was unaffected by FFP transfusion (endogenous thrombin potential, 72% [IQR 51-88] before vs. 71% [IQR 42-89] after), whereas ROTEM EXTEM clotting time and maximum clot firmness slightly improved in response to FFP.
In non-bleeding critically ill patients with a coagulopathy, FFP transfusion failed to induce a more procoagulant state.
凝血障碍在危重症患者中发病率很高。国际标准化比值(INR)升高是输注新鲜冷冻血浆(FFP)的常见触发因素,即使在没有出血的情况下也是如此。因此,经常给这些患者输注 FFP。然而,FFP 纠正非出血性接受者止血障碍的疗效一直存在争议。
评估 INR 延长是否与其他凝血检测结果的变化平行,并评估凝血因子固定剂量对凝血障碍非出血性危重症患者的凝血作用。
测定凝血标志物、单个因子水平和天然抗凝剂水平。还在输注 FFP(12 mL/kg)前后(1.5-3.0)对 38 名凝血障碍非出血性危重症患者进行凝血酶生成和血栓弹力图(ROTEM)检测。
在基线时,因子 II、FV、FVII、蛋白 C、蛋白 S 和抗凝血酶水平降低,凝血酶生成受损。ROTEM 变量在参考范围内,除 INTEM 凝块形成时间延长外。FFP 输注增加了凝血因子的水平(FII,34%[四分位距(IQR)26-46],输注前 vs. 44%[IQR 38-52],输注后;FV,48%[IQR 28-76],输注前 vs. 58%[IQR 44-90],输注后;FVII,25%[IQR 16-38],输注前 vs. 37%[IQR 28-55],输注后)和抗凝蛋白的水平。凝血酶生成不受 FFP 输注的影响(内源性凝血酶潜能,72%[IQR 51-88],输注前 vs. 71%[IQR 42-89],输注后),而 ROTEM EXTEM 凝血时间和最大凝块硬度在 FFP 反应下略有改善。
在凝血障碍非出血性危重症患者中,FFP 输注未能诱导更促凝状态。